MAESTrO: Coagulation factor IX FC fusion protein (Alprolix): treatment cost comparison and budget impact analysis

Posted by Michael Wonder on 12 Nov 2015

Coagulation factor IX FC fusion protein (Alprolix): treatment cost comparison and budget impact analysis

9 November 2015 - CADTH's final science report is now available for the project on coagulation factor IX FC fusion protein (Alprolix): treatment cost comparison and budget impact analysis.

For more details, go to: https://www.cadth.ca/coagulation-factor-ix-fc-fusion-protein-alprolix-treatment-cost-comparison-and-budget-impact

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Canada , Affordability , Blood product , Budget impact analysis